Immunovant (IMVT) Debt Ratio (2019 - 2023)

Immunovant's (IMVT) quarterly Debt Ratio came in at 0.0 in Q1 2023, up 160.02% YoY from 0.0 in Q1 2022, and up 160.02% on a QoQ basis from 0.0 in Q1 2022.

Immunovant (IMVT) Debt Ratio (2019 - 2023) Analysis & Trends

Immunovant (IMVT) has 4 years of Debt Ratio data on file, last reported at 0.0 in Q1 2023.

  • Quarterly Debt Ratio rose 160.02% year-over-year to 0.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was 0.0 (up 160.02% YoY) and the FY2023 annual result came in at 0.0, up 160.02% from the prior year.
  • Debt Ratio advanced to 0.0 in Q1 2023, from 0.0 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.04 in Q2 2019 to a low of 0.0 in Q3 2020.
  • A 4-year average of 0.01 and a median of 0.0 in 2019 frame the typical range for Debt Ratio.
  • The widest YoY moves for Debt Ratio: up 595.27% in 2020, down 98.61% in 2020.
  • Tracing IMVT's Debt Ratio over 4 years: stood at 0.02 in 2019, then plunged by 98.81% to 0.0 in 2020, then climbed by 12.35% to 0.0 in 2022, then jumped by 160.02% to 0.0 in 2023.
  • The last three Debt Ratio figures came in at 0.0 (Q1 2023), 0.0 (Q1 2022), and 0.0 (Q3 2020), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 0.05
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 0.12
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 0.47
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 0.26
10 Immunovant 8.63 Bn 7.83 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2023 0.00
Mar 31, 2022 0.00
Sep 30, 2020 0.00
Jun 30, 2020 0.00
Mar 31, 2020 0.03
Dec 31, 2019 0.02
Sep 30, 2019 0.02
Jun 30, 2019 0.04
Mar 31, 2019 0.00